The Journal of Clinical Psychiatry
A Placebo-Controlled 18-Month Trial of Lamotrigine and Lithium Maintenance Treatment in Recently Depressed Patients With Bipolar I Disorder
What this article backs
- Lamotrigine Treatment Relapse Rate
- Lithium Treatment Relapse Rate
- Lamotrigine Treatment Depressive Episode
- Lithium Treatment Manic Episode
- Lamotrigine Treatment decreases Relapse Rate.
- Lithium Treatment decreases Relapse Rate.
- Lamotrigine Treatment prevents Depressive Episode.
- Lithium Treatment prevents Manic Episode.
In its own words
Lithium was statistically superior to placebo at prolonging the time to intervention for a manic or hypomanic episode (p = .026). The proportions of patients who were intervention-free for mania at 1 year were lamotrigine 77%, lithium 86%, and placebo 72%
Lamotrigine was statistically superior to placebo at prolonging the time to intervention for a depressive episode (p = .047). The proportions of patients who were intervention-free for depression at 1 year were lamotrigine 57%
Time to intervention for any mood episode was statistically superior (p = .029) for both lamotrigine and lithium compared with placebo-median survival times were 200, 170, and 93 days
Corroborated by
More from The Journal of Clinical Psychiatry
-
Suicide and Attempted Suicide in Bipolar Disorder: A Systematic Review of Risk Factors
Backs 10 claims- Previous Suicide Attempt Suicide Risk
- Hopelessness Suicide Risk
- Family History Of Mood Disorder Suicide Risk
- Early Episode Onset Suicide Risk
- Depressive Episode Suicide Risk
- Bipolar Disorder Severity Suicide Risk
- Mixed Episode Suicide Risk
- Rapid Cycling Suicide Risk
- Anxiety Comorbidity Suicide Risk
- Substance Use Suicide Risk
